Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment

被引：26

作者：

Lachowiez, Curtis A. ^{[1
]}

Reville, Patrick K. ^{[1
]}

Kantarjian, Hagop ^{[2
]}

Jabbour, Elias ^{[2
]}

Borthakur, Gautam ^{[2
]}

Daver, Naval ^{[2
]}

Issa, Ghayas ^{[2
]}

Furudate, Ken ^{[3
]}

Tanaka, Tomoyuki ^{[3
]}

Pierce, Sherry ^{[2
]}

Tang, Guilin ^{[4
]}

Patel, Keyur P.

Medeiros, Jeffrey

Abbas, Hussein A. ^{[2
]}

Haddad, Fadi ^{[2
]}

Hammond, Daniel ^{[2
]}

Short, Nicholas J. ^{[2
]}

Maiti, Abhishek ^{[2
]}

Yilmaz, Musa ^{[2
]}

Sasaki, Koji ^{[2
]}

Takahashi, Koichi ^{[2
]}

Pemmaraju, Naveen ^{[2
]}

Konopleva, Marina ^{[2
]}

Garcia-Manero, Guillermo ^{[2
]}

Ravandi, Farhad ^{[2
]}

Kadia, Tapan M. ^{[2
]}

Loghavi, Sanam ^{[4
]}

DiNardo, Courtney D. ^{[2
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Div Canc Med, Houston, TX 77030 USA

[2] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[3] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA

[4] Univ Texas MD Anderson Canc Ctr, Dept hematopathol, Houston, TX 77030 USA

来源：

AMERICAN JOURNAL OF HEMATOLOGY | 2022年 / 97卷 / 11期

关键词：

PROGNOSTIC-SIGNIFICANCE; AML; RECOMMENDATIONS; AZACITIDINE; DIAGNOSIS;

D O I：

10.1002/ajh.26694

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Isocitrate dehydrogenase 1 or 2 (IDH1 or IDH2) mutations occur frequently in newly diagnosed (ND) acute myeloid leukemia (AML) often with co-occurring NPM1 mutations, which may influence treatment outcomes. Detailed analysis of IDH-mutated AML treated with venetoclax and influence of co-occurring NPM1 mutations remains unclear. This retrospective single-center cohort study evaluated clinical and molecular demographics,response and survival, and impact of co-occurring NPM1 mutations in patients with IDH1 or IDH2-mutated AML. 556 patients with IDH1, IDH2, and/or NPM1 mutated AML were included. Patients with IDH1(mut) AML (N = 119) were more likely to have older age, sAML, ELN-adverse risk disease, and adverse-risk cytogenetics compared to those with IDH2(mut) (N = 229) or IDHwt/NPM1(mut) AML (N = 208). In multivariate analysis, patients with IDH2(mut) (HR 0.61 [95%CI: 0.43-0.88], p value: .007) or IDHwt/NPM1(mut) (HR 0.65 [95% CI: 0.45-0.94], p value: .024) AML had a decreased risk of death versus IDH1(mut) AML. Venetoclax-based lower-intensity regimens partially abrogated the detrimental effect of IDH1(mut) with similar OS observed between IDH1(mut)/NPM1(wt), IDH2(mut)/NPM1(wt), and IDHwt/NPM1(mut) AML. With regards to the influence of IDHmut/NPM1(mut) cases, IC improved survival in IDH2(mut)/NPM1(mut) versus IDH2(mut)/NPM1(wt) AML (HR: 0.54 [95% CI: 0.2644-1.082], p value: .077), while venetoclax-based therapy improved survival in IDH1(mut)/NPM1(mut) versus IDH1(mut)/NPM1(wt) AML (HR: 0.094 [95% CI: 0.01-0.74], p value: .0056). Differing outcomes were observed in IDH1(mut) versus IDH2(mut) or NPM1(mut) AML which were influenced by co-occurring NPM1 mutations and partially abrogated with venetoclax-based therapy. Given the differing biology and survival in IDH1(mut) AML, investigations incorporating molecularly targeted therapies such as IDH inhibitors remain warranted in this subgroup.

引用

页码：1443 / 1452

页数：10

共 44 条

[31] Prognostic Impact of Concurrent DNMT3A, FLT3 and NPM1 Gene Mutations in Acute Myeloid Leukemia Patients [J].

Abd Elrhman, Heba Allah E. ;

El-Meligui, Yomna M. ;

Elalawi, Saffaa M. .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (12) :E960-E969

[32] Myelomonocytic and monocytic acute myeloid leukemia demonstrate comparable poor outcomes with venetoclax-based treatment: a monocentric real-world study [J].

Zhao, Lei ;

Yang, Jinjun ;

Chen, Mengran ;

Xiang, Xinrong ;

Ma, Hongbing ;

Niu, Ting ;

Gong, Yuping ;

Chen, Xinchuan ;

Liu, Jiazhuo ;

Wu, Yu .

ANNALS OF HEMATOLOGY, 2024, 103 (04) :1197-1209

[33] Prognostic impact of white blood cell count in intermediate risk acute myeloid leukemia: relevance of mutated NPM1 and FLT3-ITD [J].

de Jonge, Hendrik J. M. ;

Valk, Peter J. M. ;

de Bont, Eveline S. J. M. ;

Schuringa, Jan Jacob ;

Ossenkoppele, Gert ;

Vellenga, Edo ;

Huls, Gerwin .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2011, 96 (09) :1310-1317

[34] Prognostic impact of early minimal residual disease combined with complete molecular evaluation in acute myeloid leukemia with mutated NPM1: a single center study [J].

Memoli, Mara ;

Genthon, Alexis ;

Favale, Fabrizia ;

Lapusan, Simona ;

Johnson, Natacha ;

Adaeva, Rosa ;

Deswarte, Caroline ;

Battipaglia, Giorgia ;

Malard, Florent ;

Dulery, Remy ;

Brissot, Eolia ;

Banet, Anne ;

Van de Wyngaert, Zoe ;

Mohty, Mohamad ;

Delhommeau, Francois ;

Legrand, Ollivier ;

Hirsch, Pierre .

LEUKEMIA & LYMPHOMA, 2022, 63 (09) :2171-2179

[35] The prognostic impact of FLT3-ITD and NPM1 mutations in patients with relapsed acute myeloid leukemia and intermediate-risk cytogenetics [J].

How, J. ;

Sykes, J. ;

Minden, M. D. ;

Gupta, V. ;

Yee, K. W. L. ;

Schimmer, A. D. ;

Schuh, A. C. ;

Kamel-Reid, S. ;

Brandwein, J. M. .

BLOOD CANCER JOURNAL, 2013, 3 :e116-e116

[36] Molecular subtypes of NPM1 mutations have different clinical profiles, specific patterns of accompanying molecular mutations and varying outcomes in intermediate risk acute myeloid leukemia [J].

Alpermann, Tamara ;

Schnittger, Susanne ;

Eder, Christiane ;

Dicker, Frank ;

Meggendorfer, Manja ;

Kern, Wolfgang ;

Schmid, Christoph ;

Aul, Carlo ;

Staib, Peter ;

Wendtner, Clemens-Martin ;

Schmitz, Norbert ;

Haferlach, Claudia ;

Haferlach, Torsten .

HAEMATOLOGICA, 2016, 101 (02) :E55-E58

[37] Prognostic Significance of CEBPA Mutations in a Large Cohort of Younger Adult Patients With Acute Myeloid Leukemia: Impact of Double CEBPA Mutations and the Interaction With FLT3 and NPM1 Mutations [J].

Green, Claire L. ;

Koo, Kenneth K. ;

Hills, Robert K. ;

Burnett, Alan K. ;

Linch, David C. ;

Gale, Rosemary E. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (16) :2739-2747

[38] Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3, IDH and NPM1 Mutations in Acute Myeloid Leukemia: Results of the PETHEMA PCR-LMA Study [J].

Boluda, Blanca ;

Rodriguez-Veiga, Rebeca ;

Sargas, Claudia ;

Ayala, Rosa ;

Larrayoz, Maria J. ;

Chillon, Maria Carmen ;

Soria-Saldise, Elena ;

Bilbao, Cristina ;

de la Torre, Esther Prados ;

Navarro, Irene ;

Martinez-Cuadron, David ;

Gil, Cristina ;

Bernal, Teresa ;

Bergua, Juan ;

Algarra, Lorenzo ;

Tormo, Mar ;

Martinez-Sanchez, Pilar ;

Carrillo-Cruz, Estrella ;

Serrano, Josefina ;

Alonso-Dominguez, Juan M. ;

Garcia, Raimundo ;

Amigo, Maria Luz ;

Herrera-Puente, Pilar ;

Sayas, Maria J. ;

Lavilla-Rubira, Esperanza ;

Garcia-Perez, Maria Jose ;

Moran, Julia ;

Perez-Santaolalla, Esther ;

Alonso-Vence, Natalia ;

Oliva, Ana ;

Lopez, Juan Antonio ;

Barrios, Manuel ;

Garcia-Fortes, Maria ;

Olave, Maria Teresa ;

Labrador, Jorge ;

Martinez-Lopez, Joaquin ;

Calasanz, Maria J. ;

Garcia-Sanz, Ramon ;

Perez-Simon, Jose A. ;

Gomez-Casares, Maria T. ;

Sanchez-Garcia, Joaquin ;

Mendizabal, Yolanda ;

Barragan, Eva ;

Montesinos, Pau ;

PETHEMA Grp .

CANCERS, 2025, 17 (05)

[39] Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3-mutant acute myeloid leukemia [J].

Dalle, Iman Abou ;

Ghorab, Ahmad ;

Patel, Keyur ;

Wang, Xuemei ;

Hwang, Hyunsoo ;

Cortes, Jorge ;

Issa, Ghayas C. ;

Yalniz, Fevzi ;

Sasaki, Koji ;

Chihara, Dai ;

Price, Allyson ;

Kadia, Tapan ;

Pemmaraju, Naveen ;

Daver, Naval ;

DiNardo, Courtney ;

Ravandi, Farhad ;

Kantarjian, Hagop M. ;

Borthakur, Gautam .

BLOOD CANCER JOURNAL, 2020, 10 (05)

[40] Preclinical Validation of an Advanced Therapy Medicinal Product Based on Cytotoxic T Lymphocytes Specific for Mutated Nucleophosmin (NPM1mut) for the Treatment of NPM1mut-Acute Myeloid Leukemia [J].

De Cicco, Marica ;

Lagreca, Ivana ;

Basso, Sabrina ;

Barozzi, Patrizia ;

Muscianisi, Stella ;

Bianco, Alba ;

Riva, Giovanni ;

Di Vincenzo, Sara ;

Pulvirenti, Chiara ;

Sapuppo, Davide ;

Siciliano, Mariangela ;

Rosti, Vittorio ;

Candoni, Anna ;

Zecca, Marco ;

Forghieri, Fabio ;

Luppi, Mario ;

Comoli, Patrizia .

CANCERS, 2023, 15 (10)

← 1 2 3 4 5 →